Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment.
暂无分享,去创建一个
Bansri Desai | T Joseph Mattingly | Remon W M van den Broek | Ngan Pham | Megan Frailer | Joseph Yang | Eleanor M Perfetto | E. Perfetto | T. Mattingly | R. V. D. van den Broek | B. Desai | N. Pham | M. Frailer | Joseph Yang | Remon W.M. van den Broek
[1] F. Collins,et al. Policy: NIH plans to enhance reproducibility , 2014, Nature.
[2] Maarten J. IJzerman,et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] A. DeMaria. Peer review: better than the alternatives. , 2002, Journal of the American College of Cardiology.
[4] Athina Tatsioni,et al. Who is afraid of reviewers’ comments? Or, why anything can be published and anything can be cited , 2010, European journal of clinical investigation.
[5] Jennifer M. Urban,et al. Shining Light into Black Boxes , 2012, Science.
[6] J. Sharfstein,et al. Enhancing Transparency at the US Food and Drug Administration: Moving Beyond the 21st Century Cures Act. , 2017, JAMA.
[7] S. Goodman,et al. Reproducible Research: Moving toward Research the Public Can Really Trust , 2007, Annals of Internal Medicine.
[8] Aris Angelis,et al. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries , 2017, The European Journal of Health Economics.
[9] J. Denis,et al. Use of health technology assessment in decision making: Coresponsibility of users and producers? , 2005, International Journal of Technology Assessment in Health Care.
[10] H. Kölsch,et al. Reporting bias in medical research - a narrative review , 2010, Trials.
[11] Harpreet S. Kohli,et al. Health Technology Assessment and Health Policy-Making in Europe – Current Status, Challenges and Potential , 2010 .
[12] Carol Tenopir,et al. Trustworthiness and authority of scholarly information in a digital age: Results of an international questionnaire , 2016, J. Assoc. Inf. Sci. Technol..
[13] Guido Rasi,et al. Transparency and the European Medicines Agency--sharing of clinical trial data. , 2014, The New England journal of medicine.
[14] S. Sullivan,et al. Economic Evaluation in the US , 2012, PharmacoEconomics.
[15] Louis P Garrison,et al. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] Olaf Klungel,et al. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0 , 2017, Pharmacoepidemiology and drug safety.
[17] Richard Smith,et al. Peer Review: A Flawed Process at the Heart of Science and Journals , 2006, Journal of the Royal Society of Medicine.
[18] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[19] R. Spier. The history of the peer-review process. , 2002, Trends in biotechnology.
[20] J. Ioannidis,et al. Reproducible research practices, transparency, and open access data in the biomedical literature, 2015–2017 , 2018, PLoS biology.
[21] Scott D Ramsey,et al. Health technology assessment in health-care decisions in the United States. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.